# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
B of A Securities analyst Michael Funk downgrades Cencora (NYSE:COR) from Buy to Neutral and lowers the price target from $2...
Baird analyst David Rodgers maintains Cencora (NYSE:COR) with a Outperform and lowers the price target from $287 to $283.
Three major U.S. drug distributors, McKesson, Cencora, and Cardinal Health, have agreed to a $300 million settlement over claim...
JP Morgan analyst Lisa Gill maintains Cencora (NYSE:COR) with a Overweight and raises the price target from $280 to $287.